Julius J. Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julius J. Schmidt has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Jan Thomas Kielstein
Medical Clinic V, Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital, Braunschweig, Germany
7 shared publications - Sascha David
Institut für Intensivmedizin, Universitätsspital Zürich, Zürich, Schweiz
7 shared publications - Benjamin Seeliger
Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany
6 shared publications - Klaus Stahl
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
5 shared publications - Tobias Welte
Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany
5 shared publications - Bernhard Magnus Wilhelm Schmidt
Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
4 shared publications
Latest Publications
- 19 January 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (2)
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
Objectives: Cefiderocol is a new siderophore cephalosporin for treating severe bacterial infections by Gram-negative pathogens in adults. Significant elimination of the drug will probably occur as a result of kidney replacement therapy, but there are currently insufficient pharmacokinetic data to guide dosing during prolonged intermittent kidney replacement therapy (PIKRT) or the use of the pathogen adsorber Seraph 100. Materials and methods/case reports: Pharmacokinetic data were obtained from two critically ill patients undergoing PIKRT and hemoperfusion with the pathogen adsorber Seraph 100. Cefiderocol levels in plasma and dialysate samples were quantified using liquid chromatography with tandem mass spectrometry to evaluate the impact of extracorporeal therapy modalities on cefiderocol pharmacokinetics. Results: The median cefiderocol dialyser clearance was 80.94 (38.7–87) mL/min, while the Seraph 100 showed no significant clearance [−1.8 (−7.9 to 3.6) mL/min]. The cefiderocol concentration in the total spent dialysate suggests a total elimination of 1350 and 400 mg of cefiderocol, or 68% and 40% of the administered dose. Conclusion: Cefiderocol is substantially eliminated by PIKRT, but not during hemoperfusion with the Seraph 100. Consequently, dosage adjustments may be necessary depending on the intensity of the PIKRT procedure. Doses used for patients with normal renal function may be required to prevent underdosing during intensive PIKRT.
- 19 January 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (2)
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
Objectives: Cefiderocol is a new siderophore cephalosporin for treating severe bacterial infections by Gram-negative pathogens in adults. Significant elimination of the drug will probably occur as a result of kidney replacement therapy, but there are currently insufficient pharmacokinetic data to guide dosing during prolonged intermittent kidney replacement therapy (PIKRT) or the use of the pathogen adsorber Seraph 100. Materials and methods/case reports: Pharmacokinetic data were obtained from two critically ill patients undergoing PIKRT and hemoperfusion with the pathogen adsorber Seraph 100. Cefiderocol levels in plasma and dialysate samples were quantified using liquid chromatography with tandem mass spectrometry to evaluate the impact of extracorporeal therapy modalities on cefiderocol pharmacokinetics. Results: The median cefiderocol dialyser clearance was 80.94 (38.7–87) mL/min, while the Seraph 100 showed no significant clearance [−1.8 (−7.9 to 3.6) mL/min]. The cefiderocol concentration in the total spent dialysate suggests a total elimination of 1350 and 400 mg of cefiderocol, or 68% and 40% of the administered dose. Conclusion: Cefiderocol is substantially eliminated by PIKRT, but not during hemoperfusion with the Seraph 100. Consequently, dosage adjustments may be necessary depending on the intensity of the PIKRT procedure. Doses used for patients with normal renal function may be required to prevent underdosing during intensive PIKRT.
- 9 October 2024
- Published by Elsevier in Journal of Critical Care
- Vol. 85, 154927
Circulating soluble urokinase plasminogen receptor is reduced by - and predicts early treatment response to therapeutic plasma exchange in septic shock
- 9 October 2024
- Published by Elsevier in Journal of Critical Care
- Vol. 85, 154927
Circulating soluble urokinase plasminogen receptor is reduced by - and predicts early treatment response to therapeutic plasma exchange in septic shock
- 3 June 2024
- Published by Springer Nature in Die Nephrologie
- Vol. 19 (4) , 1-7
“Let’s double-click on that”
- 3 June 2024
- Published by Springer Nature in Die Nephrologie
- Vol. 19 (4) , 1-7
“Let’s double-click on that”
- Open Access
- 1 February 2024
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 171 (2) , 020555
Investigating the Path Dependent Aging Behavior of Nickel Cobalt Aluminum Oxide Cathode Batteries During High C-rate Cycling Conditions
Nickel-rich cathode material batteries such as the nickel cobalt aluminum oxide with graphite anode are common in the automotive sector due to their high energy density and power performance capabilities, however, they are limited in lifetime performance. Accelerated degradation in specific operation conditions, such as high C-rates are known to significantly contribute to this issue. To better understand a chronological dependence of these high-stress conditions occurring during battery lifetime, a path dependent aging study is performed using profiles inspired by high-performance race operation. The focus on C-rates >1C during charging and discharging using real-world inspired profiles- known to induce particle cracking or lithium plating- addresses the need to understand aging behavior in less studied, but highly relevant high-performance automotive context. The aging conditions were tailored to induce specific degradation modes to better identify potential degradation mode coupling. Using differential voltage and capacity analysis techniques, degradation modes were identified which likely contributed to path dependent aging behavior, including loss of lithium inventory and loss of active material in the positive electrode. Two critical paths were identified in this study where later high C-rate conditions in the form of fast-charging at temperatures of 25 °C resulted in accelerated aging and where loss of lithium inventory induced stresses in the positive electrode, accelerating loss of active material.
- 1 February 2024
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 171 (2) , 020555
Open AccessInvestigating the Path Dependent Aging Behavior of Nickel Cobalt Aluminum Oxide Cathode Batteries During High C-rate Cycling Conditions
Nickel-rich cathode material batteries such as the nickel cobalt aluminum oxide with graphite anode are common in the automotive sector due to their high energy density and power performance capabilities, however, they are limited in lifetime performance. Accelerated degradation in specific operation conditions, such as high C-rates are known to significantly contribute to this issue. To better understand a chronological dependence of these high-stress conditions occurring during battery lifetime, a path dependent aging study is performed using profiles inspired by high-performance race operation. The focus on C-rates >1C during charging and discharging using real-world inspired profiles- known to induce particle cracking or lithium plating- addresses the need to understand aging behavior in less studied, but highly relevant high-performance automotive context. The aging conditions were tailored to induce specific degradation modes to better identify potential degradation mode coupling. Using differential voltage and capacity analysis techniques, degradation modes were identified which likely contributed to path dependent aging behavior, including loss of lithium inventory and loss of active material in the positive electrode. Two critical paths were identified in this study where later high C-rate conditions in the form of fast-charging at temperatures of 25 °C resulted in accelerated aging and where loss of lithium inventory induced stresses in the positive electrode, accelerating loss of active material.
- 10 October 2022
- Published by Walter de Gruyter GmbH
- p. 179-218
10 Organversagen und Organersatz
10 Organversagen und Organersatz was published in Sepsis on page 179.
- 10 October 2022
- Published by Walter de Gruyter GmbH
- p. 179-218
10 Organversagen und Organersatz
10 Organversagen und Organersatz was published in Sepsis on page 179.
- 23 August 2022
- Published by Elsevier in Journal of Critical Care
- Vol. 72, 154139
Therapeutic plasma exchange in patients with acute pancreatitis associated refractory shock and multi-organ failure
- 23 August 2022
- Published by Elsevier in Journal of Critical Care
- Vol. 72, 154139
Therapeutic plasma exchange in patients with acute pancreatitis associated refractory shock and multi-organ failure
- Open Access
- 17 June 2022
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-11
Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study
Background: Bacterial burden as well as duration of bacteremia influence the outcome of patients with bloodstream infections. Promptly decreasing bacterial load in the blood by using extracorporeal devices in addition to anti-infective therapy has recently been explored. Preclinical studies with the Seraph® 100 Microbind® Affinity Blood Filter (Seraph® 100), which consists of heparin that is covalently bound to polymer beads, have demonstrated an effective binding of bacteria and viruses. Pathogens adhere to the heparin coated polymer beads in the adsorber as they would normally do to heparan sulfate on cell surfaces. Using this biomimetic principle, the Seraph® 100 could help to decrease bacterial burden in vivo. Methods: This first in human, prospective, multicenter, non-randomized interventional study included patients with blood culture positive bloodstream infection and the need for kidney replacement therapy as an adjunctive treatment for bloodstream infections. We performed a single four-hour hemoperfusion treatment with the Seraph® 100 in conjunction with a dialysis procedure. Post procedure follow up was 14 days. Results: Fifteen hemodialysis patients (3F/12 M, age 74.0 [68.0–78.5] years, dialysis vintage 28.0 [11.0–45.0] months) were enrolled. Seraph® 100 treatment started 66.4 [45.7–80.6] hours after the initial positive blood culture was drawn. During the treatment with the Seraph® 100 with a median blood flow of 285 [225–300] ml/min no device or treatment related adverse events were reported. Blood pressure and heart rate remained stable while peripheral oxygen saturation improved during the treatment from 98.0 [92.5–98.0] to 99.0 [98.0–99.5] %; p = 0.0184. Four patients still had positive blood culture at the start of Seraph® 100 treatment. In one patient blood cultures turned negative during treatment. The time to positivity (TTP) was increased between inflow and outflow blood cultures by 36 [− 7.2 to 96.3] minutes. However, overall TTP increase was not statistical significant. Conclusions: Seraph® 100 treatment was well tolerated. Adding Seraph® 100 to antibiotics early in the course of bacteremia might result in a faster resolution of bloodstream infections, which has to be evaluated in further studies. Trail registration: ClinicalTrials.gov Identifier: NCT02914132, first posted September 26, 2016.
- 17 June 2022
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-11
Open AccessSafety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study
Background: Bacterial burden as well as duration of bacteremia influence the outcome of patients with bloodstream infections. Promptly decreasing bacterial load in the blood by using extracorporeal devices in addition to anti-infective therapy has recently been explored. Preclinical studies with the Seraph® 100 Microbind® Affinity Blood Filter (Seraph® 100), which consists of heparin that is covalently bound to polymer beads, have demonstrated an effective binding of bacteria and viruses. Pathogens adhere to the heparin coated polymer beads in the adsorber as they would normally do to heparan sulfate on cell surfaces. Using this biomimetic principle, the Seraph® 100 could help to decrease bacterial burden in vivo. Methods: This first in human, prospective, multicenter, non-randomized interventional study included patients with blood culture positive bloodstream infection and the need for kidney replacement therapy as an adjunctive treatment for bloodstream infections. We performed a single four-hour hemoperfusion treatment with the Seraph® 100 in conjunction with a dialysis procedure. Post procedure follow up was 14 days. Results: Fifteen hemodialysis patients (3F/12 M, age 74.0 [68.0–78.5] years, dialysis vintage 28.0 [11.0–45.0] months) were enrolled. Seraph® 100 treatment started 66.4 [45.7–80.6] hours after the initial positive blood culture was drawn. During the treatment with the Seraph® 100 with a median blood flow of 285 [225–300] ml/min no device or treatment related adverse events were reported. Blood pressure and heart rate remained stable while peripheral oxygen saturation improved during the treatment from 98.0 [92.5–98.0] to 99.0 [98.0–99.5] %; p = 0.0184. Four patients still had positive blood culture at the start of Seraph® 100 treatment. In one patient blood cultures turned negative during treatment. The time to positivity (TTP) was increased between inflow and outflow blood cultures by 36 [− 7.2 to 96.3] minutes. However, overall TTP increase was not statistical significant. Conclusions: Seraph® 100 treatment was well tolerated. Adding Seraph® 100 to antibiotics early in the course of bacteremia might result in a faster resolution of bloodstream infections, which has to be evaluated in further studies. Trail registration: ClinicalTrials.gov Identifier: NCT02914132, first posted September 26, 2016.
- Open Access
- 12 May 2022
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-14
Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial
Background: Recently, a randomized controlled trial (RCT) demonstrated rapid but individually variable hemodynamic improvement with therapeutic plasma exchange (TPE) in patients with septic shock. Prediction of clinical efficacy in specific sepsis treatments is fundamental for individualized sepsis therapy. Methods: In the original RCT, patients with septic shock of < 24 h duration and norepinephrine (NE) requirement ≥ 0.4 μg/kg/min received standard of care (SOC) or SOC + one single TPE. Here, we report all clinical and biological endpoints of this study. Multivariate mixed-effects modeling of NE reduction was performed to investigate characteristics that could be associated with clinical response to TPE. Results: A continuous effect of TPE on the reduction in NE doses over the initial 24 h was observed (SOC group: estimated NE dose reduction of 0.005 µg/kg/min per hour; TPE group: 0.018 µg/kg/min per hour, p = 0.004). Similarly, under TPE, serum lactate levels, continuously decreased over the initial 24 h in the TPE group, whereas lactate levels increased under SOC (p = 0.001). A reduction in biomarkers and disease mediators (such as PCT (p = 0.037), vWF:Ag (p < 0.001), Angpt-2 (p = 0.009), sTie-2 (p = 0.005)) along with a repletion of exhausted protective factors (such as AT-III (p = 0.026), Protein C (p = 0.012), ADAMTS-13 (p = 0.008)) could be observed in the TPE but not in the SOC group. In a multivariate mixed effects model, increasing baseline lactate levels led to greater NE dose reduction effects with TPE as opposed to SOC (p = 0.004). Conclusions: Adjunctive TPE is associated with the removal of injurious mediators and repletion of consumed protective factors altogether leading to preserved hemodynamic stabilization in refractory septic shock. We identified that baseline lactate concentration as a potential response predictor might guide future designing of large RCTs that will further evaluate TPE with regard to hard endpoints. Trial registration Retrospectively registered 18th January 2020 at clinicaltrials.gov (Identifier: NCT04231994).
- 12 May 2022
- Published by Springer Nature in Critical Care
- Vol. 26 (1) , 1-14
Open AccessClinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial
Background: Recently, a randomized controlled trial (RCT) demonstrated rapid but individually variable hemodynamic improvement with therapeutic plasma exchange (TPE) in patients with septic shock. Prediction of clinical efficacy in specific sepsis treatments is fundamental for individualized sepsis therapy. Methods: In the original RCT, patients with septic shock of < 24 h duration and norepinephrine (NE) requirement ≥ 0.4 μg/kg/min received standard of care (SOC) or SOC + one single TPE. Here, we report all clinical and biological endpoints of this study. Multivariate mixed-effects modeling of NE reduction was performed to investigate characteristics that could be associated with clinical response to TPE. Results: A continuous effect of TPE on the reduction in NE doses over the initial 24 h was observed (SOC group: estimated NE dose reduction of 0.005 µg/kg/min per hour; TPE group: 0.018 µg/kg/min per hour, p = 0.004). Similarly, under TPE, serum lactate levels, continuously decreased over the initial 24 h in the TPE group, whereas lactate levels increased under SOC (p = 0.001). A reduction in biomarkers and disease mediators (such as PCT (p = 0.037), vWF:Ag (p < 0.001), Angpt-2 (p = 0.009), sTie-2 (p = 0.005)) along with a repletion of exhausted protective factors (such as AT-III (p = 0.026), Protein C (p = 0.012), ADAMTS-13 (p = 0.008)) could be observed in the TPE but not in the SOC group. In a multivariate mixed effects model, increasing baseline lactate levels led to greater NE dose reduction effects with TPE as opposed to SOC (p = 0.004). Conclusions: Adjunctive TPE is associated with the removal of injurious mediators and repletion of consumed protective factors altogether leading to preserved hemodynamic stabilization in refractory septic shock. We identified that baseline lactate concentration as a potential response predictor might guide future designing of large RCTs that will further evaluate TPE with regard to hard endpoints. Trial registration Retrospectively registered 18th January 2020 at clinicaltrials.gov (Identifier: NCT04231994).
- Open Access
- 1 April 2022
- Published by Springer Nature in Research Square
Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream – results of the first in human study
Background: The outcome of patients with bacteremia depends on both, the bacterial burden as well as the duration of bacteremia. Promptly decreasing bacterial load in the blood by using extracorporeal devices in addition to anti-infective therapy has recently been explored. Preclinical studies with Seraph® 100 Microbind® Affinity Blood Filter (Seraph® 100), which consists of heparin that is covalently bound to polymer beads, have demonstrated an effective binding of bacteria and viruses. Pathogens adhere to the heparin coated polymer beads in Seraph® 100 as they would normally do to heparan sulfate on cell surfaces. Using this biomimetic principle, the Seraph® 100 could help to decrease bacterial burden in vivo.Methods: This first in human, prospective, multicenter, non-randomized interventional study included patients with blood culture positive bloodstream infection and the need for renal replacement therapy as an adjunctive treatment for bloodstream infection. We performed a single four-hour hemoperfusion treatment with the Seraph® 100 in conjunction with a dialysis procedure. Post procedure follow up was 14 days.Results: Fifteen hemodialysis patients (3F/12M, age 74.0 [68.0 - 78.5] years, dialysis vintage 28.0 [11.0 - 45.0] months) were enrolled. Seraph® 100 treatment started 66.4 [45.7 - 80.6] hours after the positive initial blood culture was drawn. During the treatment with the Seraph® 100 with a median blood flow of 285 [225 - 300] ml/min no device or treatment related adverse events were reported. Blood pressure and heart rate remained stable while peripheral oxygen saturation improved during the treatment from 98.0 [92.5 - 98.0] to 99.0 [98.0 - 99.5] %; p = 0.0184. Four patients still had positive blood culture at the start of Seraph® 100 treatment. In one patient blood cultures turned negative during treatment. The time to positivity (TTP) was reduced between inflow and outflow blood cultures by 36 [-7.2 – 96.3] minutes. However, overall TTP reduction was not significant.Conclusions: Seraph® 100 treatment was well tolerated. Adding Seraph® 100 to antibiotics early in the course of bacteremia might result in a faster resolution of bloodstream infections, which has to be evaluated in further studies.Trail registration: ClinicalTrials.gov Identifier: NCT02914132
- 1 April 2022
- Published by Springer Nature in Research Square
Open AccessSafety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream – results of the first in human study
Background: The outcome of patients with bacteremia depends on both, the bacterial burden as well as the duration of bacteremia. Promptly decreasing bacterial load in the blood by using extracorporeal devices in addition to anti-infective therapy has recently been explored. Preclinical studies with Seraph® 100 Microbind® Affinity Blood Filter (Seraph® 100), which consists of heparin that is covalently bound to polymer beads, have demonstrated an effective binding of bacteria and viruses. Pathogens adhere to the heparin coated polymer beads in Seraph® 100 as they would normally do to heparan sulfate on cell surfaces. Using this biomimetic principle, the Seraph® 100 could help to decrease bacterial burden in vivo.Methods: This first in human, prospective, multicenter, non-randomized interventional study included patients with blood culture positive bloodstream infection and the need for renal replacement therapy as an adjunctive treatment for bloodstream infection. We performed a single four-hour hemoperfusion treatment with the Seraph® 100 in conjunction with a dialysis procedure. Post procedure follow up was 14 days.Results: Fifteen hemodialysis patients (3F/12M, age 74.0 [68.0 - 78.5] years, dialysis vintage 28.0 [11.0 - 45.0] months) were enrolled. Seraph® 100 treatment started 66.4 [45.7 - 80.6] hours after the positive initial blood culture was drawn. During the treatment with the Seraph® 100 with a median blood flow of 285 [225 - 300] ml/min no device or treatment related adverse events were reported. Blood pressure and heart rate remained stable while peripheral oxygen saturation improved during the treatment from 98.0 [92.5 - 98.0] to 99.0 [98.0 - 99.5] %; p = 0.0184. Four patients still had positive blood culture at the start of Seraph® 100 treatment. In one patient blood cultures turned negative during treatment. The time to positivity (TTP) was reduced between inflow and outflow blood cultures by 36 [-7.2 – 96.3] minutes. However, overall TTP reduction was not significant.Conclusions: Seraph® 100 treatment was well tolerated. Adding Seraph® 100 to antibiotics early in the course of bacteremia might result in a faster resolution of bloodstream infections, which has to be evaluated in further studies.Trail registration: ClinicalTrials.gov Identifier: NCT02914132
- Open Access
- 7 February 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (3) , 1074-1087
Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19
The high incidence of thrombotic events suggests a possible role of the contact system pathway in COVID-19 pathology. In this study, we determined the altered levels of factor XII (FXII) and its activation products in critically ill patients with COVID-19 in comparison with patients with severe acute respiratory distress syndrome related to the influenza virus (acute respiratory distress syndrome [ARDS]-influenza). Compatible with those data, we found rapid consumption of FXII in COVID-19 but not in ARDS-influenza plasma. Interestingly, the lag phase in fibrin formation, triggered by the FXII activator kaolin, was not prolonged in COVID-19, as opposed to that in ARDS-influenza. Confocal and electron microscopy showed that increased FXII activation rate, in conjunction with elevated fibrinogen levels, triggered formation of fibrinolysis-resistant, compact clots with thin fibers and small pores in COVID-19. Accordingly, clot lysis was markedly impaired in COVID-19 as opposed to that in ARDS-influenza. Dysregulated fibrinolytic system, as evidenced by elevated levels of thrombin-activatable fibrinolysis inhibitor, tissue-plasminogen activator, and plasminogen activator inhibitor-1 in COVID-19 potentiated this effect. Analysis of lung tissue sections revealed widespread extra- and intravascular compact fibrin deposits in patients with COVID-19. A compact fibrin network structure and dysregulated fibrinolysis may collectively contribute to a high incidence of thrombotic events in COVID-19.
- 7 February 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (3) , 1074-1087
Open AccessAltered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19
The high incidence of thrombotic events suggests a possible role of the contact system pathway in COVID-19 pathology. In this study, we determined the altered levels of factor XII (FXII) and its activation products in critically ill patients with COVID-19 in comparison with patients with severe acute respiratory distress syndrome related to the influenza virus (acute respiratory distress syndrome [ARDS]-influenza). Compatible with those data, we found rapid consumption of FXII in COVID-19 but not in ARDS-influenza plasma. Interestingly, the lag phase in fibrin formation, triggered by the FXII activator kaolin, was not prolonged in COVID-19, as opposed to that in ARDS-influenza. Confocal and electron microscopy showed that increased FXII activation rate, in conjunction with elevated fibrinogen levels, triggered formation of fibrinolysis-resistant, compact clots with thin fibers and small pores in COVID-19. Accordingly, clot lysis was markedly impaired in COVID-19 as opposed to that in ARDS-influenza. Dysregulated fibrinolytic system, as evidenced by elevated levels of thrombin-activatable fibrinolysis inhibitor, tissue-plasminogen activator, and plasminogen activator inhibitor-1 in COVID-19 potentiated this effect. Analysis of lung tissue sections revealed widespread extra- and intravascular compact fibrin deposits in patients with COVID-19. A compact fibrin network structure and dysregulated fibrinolysis may collectively contribute to a high incidence of thrombotic events in COVID-19.